Targeting Cbl-b in cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune-checkpoint blockade, such as anti-PD1 therapy, has advanced cancer treatment but faces challenges with patient response and resistance.
• The CD28 costimulatory pathway is crucial for T cell activation, but previous agonists caused toxicity.
• Casitas B lymphoma-b (Cbl-b), a regulator of CD28 and CTLA-4 signaling, promotes an immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To explore novel therapeutic strategies targeting Cbl-b to overcome resistance to current cancer immunotherapies.
• To investigate the potential of Cbl-b inhibitors in enhancing anti-tumor immune responses and promoting tumor regression.
• To identify patient populations likely to benefit from Cbl-b inhibitor therapy.

Main Methods:

• Utilized advanced pharmaceutical screening and computational biology for novel Cbl-b targeting platforms.
• Employed genetic knock-out models and Cbl-b inhibitors in experimental settings.
• Investigated the synergistic effects of Cbl-b inhibition with PD1 blockade.

Main Results:

• Cbl-b inhibition reversed immunosuppression in the TME and stimulated cytotoxic T cell activity.
• Cbl-b targeting promoted tumor regression, particularly when combined with PD1 blockade in preclinical models.
• Developed gene expression profiles to predict patient response to Cbl-b inhibitors.

Conclusions:

• Novel Cbl-b inhibitors represent a promising therapeutic approach in immuno-oncology.
• Cbl-b targeting provides antigen-specific immune stimulation, potentially overcoming resistance to existing therapies.
• Identifying specific patient populations through gene expression profiling will be key for clinical translation.